Solvay Group of Belgium has decided to sell off its entire pharmaceuticals business to Abbott Laboratories in a €4.5 B (US$6.6 B) cash transaction. Solvay will focus on its existing non-pharma activities as the acquisition will give Abbott full control of the fenofibrate franchise and help it expand into emerging markets.